2015 AAHA/AAFP Pain Management Guidelines for Dogs and Cats*
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Pain Management in Companion Animals
CONTINUING EDUCATION TAP OUR APP Pain Management in Companion Animals Download “NCPA Mobile” Today! by Ann Philbrick, PharmD, BCPS Don’t be left out of the latest news affecting community pharmacy—download our new app, NCPA Mobile! Receive real-time updates, join the conversation on Twitter with a built-in feed, Jul. 1, 2015 (expires Jul. 1, 2018) and never miss out on breaking news affecting community pharmacy. Keep the Activity Type: Application-based app on your phone year-round for updates, news, alerts, and more from NCPA. To earn continuing education credit: ACPE Program 0207-0000-15-007-H01-P; 0207-0000-15-007-H01-T Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. 2. Describe the appropriate use, mechanism of action, and precautions for use of analgesics in the treatment of pain in dogs and cats. 3. Explain the key issues that impair the prevention of diversion in compan- ion animal owners. Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. To get the free NCPA Mobile app: 2. Describe the appropriate use, mechanism of action, and precautions for FREE ONLINE CE. To take advantage use of analgesics in the treatment of pain in dogs and cats. of free continuing pharmacy educa- iPhone and iPad users—search “NCPA 3. Explain the key issues that impair the prevention of diversion in compan- tion (CPE) for this program, pharma- ion animal owners. -
Use of Electroanalgesia and Laser Therapies As Alternatives to Opioids for Acute and Chronic Pain Management[Version 1; Peer
F1000Research 2017, 6(F1000 Faculty Rev):2161 Last updated: 04 AUG 2020 REVIEW Use of electroanalgesia and laser therapies as alternatives to opioids for acute and chronic pain management [version 1; peer review: 2 approved] Paul F. White1-3, Ofelia Loani Elvir-Lazo 3, Lidia Galeas4, Xuezhao Cao3,5 1P.O. Box 548, Gualala, CA 95445, USA 2The White Mountain Institute, The Sea Ranch, CA, USA 3Department of Anesthesiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 95445, USA 4Orlando Family Medicine, Orlando, FL, USA 5First Hospital of China Medical University, Shenyang, China v1 First published: 21 Dec 2017, 6(F1000 Faculty Rev):2161 Open Peer Review https://doi.org/10.12688/f1000research.12324.1 Latest published: 21 Dec 2017, 6(F1000 Faculty Rev):2161 https://doi.org/10.12688/f1000research.12324.1 Reviewer Status Abstract Invited Reviewers The use of opioid analgesics for postoperative pain management has contributed to the global opioid epidemic. It was recently reported 1 2 that prescription opioid analgesic use often continued after major joint replacement surgery even though patients were no longer version 1 experiencing joint pain. The use of epidural local analgesia for 21 Dec 2017 perioperative pain management was not found to be protective against persistent opioid use in a large cohort of opioid-naïve patients Faculty Reviews are review articles written by the undergoing abdominal surgery. In a retrospective study involving prestigious Members of Faculty Opinions. The over 390,000 outpatients more than 66 years of age who underwent articles are commissioned and peer reviewed minor ambulatory surgery procedures, patients receiving a prescription opioid analgesic within 7 days of discharge were 44% before publication to ensure that the final, more likely to continue using opioids 1 year after surgery. -
Pain Management E-Book
VetEdPlus E-BOOK RESOURCES Pain Management E-Book WHAT’S INSIDE Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Grapiprant for Control of Osteoarthritis Pain in Dogs Use of Acupuncture for Pain Management Regional Anesthesia for the Dentistry and Oral Surgery Patient A SUPPLEMENT TO Laser Therapy for Treatment of Joint Disease in Dogs and Cats Manipulative Therapies for Hip and Back Hypomobility in Dogs E-BOOK PEER REVIEWED CONTINUING EDUCATION Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Tamara Grubb, DVM, PhD, DACVAA Associate Professor, Anesthesia and Analgesia Washington State University College of Veterinary Medicine Pain is not always a bad thing, and all pain is not Untreated or undertreated pain can cause myriad the same. Acute (protective) pain differs from adverse effects, including but not limited to chronic (maladaptive) pain in terms of function insomnia, anorexia, immunosuppression, and treatment. This article describes the types of cachexia, delayed wound healing, increased pain pain, the reasons why chronic pain can be sensation, hypertension, and behavior changes difficult to treat, and the use of gabapentin and that can lead to changes in the human–animal amantadine for treatment of chronic pain. bond.2 Hence, we administer analgesic drugs to patients with acute pain, not to eliminate the protective portion but to control the pain ACUTE PAIN beyond that needed for protection (i.e., the pain Acute pain in response to tissue damage is often that negatively affects normal physiologic called protective pain because it causes the processes and healing). This latter type of pain patient to withdraw tissue that is being damaged decreases quality of life without providing any to protect it from further injury (e.g., a dog adaptive protective mechanisms and is thus withdrawing a paw after it steps on something called maladaptive pain. -
Breast Cancer Detection from a Urine Sample by Dog Sni Ng
Breast Cancer Detection from a Urine Sample by Dog Sning Shoko Kure ( [email protected] ) Nihon Ika Daigaku https://orcid.org/0000-0002-9536-9438 Shinya Iida Nippon Medical School Chiba Hokusoh Hospital, Department of Breast Oncology Marina Yamada Nippon Sport Science University, Faculty of Medical Science Hiroyuki Takei Nippon Medical School Hospital, Department of Breast Surgery Naoyuki Yamashita Jizankai Medical foundation Tsuboi Cancer Center Hospital Yuji Sato St. Sugar Canine Cancer Detection Training Center Masao Miyashita Nippon Medical School and Twin Peaks Laboratory of Medicine Research article Keywords: dogs, diagnosis, canine cancer detection, breast cancer, urine sample Posted Date: October 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-89484/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract Background: Breast cancer is a leading cause of cancer death worldwide. Several studies have demonstrated that dog can sniff and detect cancer in the breath or urine sample of a patient. Objective: The aim of this study is to assess whether the trained dog can detect breast cancer from urine samples. Methods: A nine-year-old female Labrador Retriever was trained to identify cancer from urine samples of breast cancer patients. Urine samples from patients histologically diagnosed with primary breast cancer, those with non-breast malignant diseases, and healthy volunteers were obtained, and a double-blind test was performed. Results: 40 patients with breast cancer, 142 patients with non-breast malignant diseases, and 18 healthy volunteers were enrolled, and their urine samples were collected. -
Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0. -
Non-Steroidal Anti-Inflammatory Drugs As Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals
Annual Research & Review in Biology 26(1): 1-13, 2018; Article no.ARRB.40829 ISSN: 2347-565X, NLM ID: 101632869 Non-Steroidal Anti-Inflammatory Drugs as Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals Bianca F. Bishop1 and Suong N. T. Ngo1* 1School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia. Authors’ contributions This work was carried out in collaboration between both authors. Author BFB performed the collection and analysis of the data. Author SNTN designed the study, managed the analyses and interpretation of the data and prepared the manuscript. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/ARRB/2018/40829 Editor(s): (1) David E. Martin, Martin Pharma Consulting, LLC, Shawnee, OK, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. Reviewers: (1) Fulya Ustun Alkan, Istanbul University, Turkey. (2) Thompson Akinbolaji, USA. (3) Ramesh Gurunathan, Sunway Medical Center, Malaysia. (4) Mohamed Ahmed Mohamed Nagy Mohamed, El Minia Hospital, Egypt. Complete Peer review History: http://www.sciencedomain.org/review-history/24385 Received 10th February 2018 Accepted 21st April 2018 Review Article Published 30th April 2018 ABSTRACT Aims: This study aims to systematically review currently available data on the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of cancer in domestic animals to evaluate the efficacy of different treatment protocols and to suggest further recommendations for future study. Methodology: Literature data on the use of NSAIDs in domestic animals as chemo-preventive agents in the last decade were collected and critically reviewed. -
VHA/Dod CLINICAL PRACTICE GUIDELINE for the MANAGEMENT of POSTOPERATIVE PAIN
VHA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF POSTOPERATIVE PAIN Veterans Health Administration Department of Defense Prepared by: THE MANAGEMENT OF POSTOPERATIVE PAIN Working Group with support from: The Office of Performance and Quality, VHA, Washington, DC & Quality Management Directorate, United States Army MEDCOM VERSION 1.2 JULY 2001/ UPDATE MAY 2002 VHA/DOD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF POSTOPERATIVE PAIN TABLE OF CONTENTS Version 1.2 Version 1.2 VHA/DoD Clinical Practice Guideline for the Management of Postoperative Pain TABLE OF CONTENTS INTRODUCTION A. ALGORITHM & ANNOTATIONS • Preoperative Pain Management.....................................................................................................1 • Postoperative Pain Management ...................................................................................................2 B. PAIN ASSESSMENT C. SITE-SPECIFIC PAIN MANAGEMENT • Summary Table: Site-Specific Pain Management Interventions ................................................1 • Head and Neck Surgery..................................................................................................................3 - Ophthalmic Surgery - Craniotomies Surgery - Radical Neck Surgery - Oral-maxillofacial • Thorax (Non-cardiac) Surgery.......................................................................................................9 - Thoracotomy - Mastectomy - Thoracoscopy • Thorax (Cardiac) Surgery............................................................................................................16 -
Systematic Scoping Review on Social Media Monitoring Methods and Interventions Relating to Vaccine Hesitancy
TECHNICAL REPORT Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy www.ecdc.europa.eu ECDC TECHNICAL REPORT Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy This report was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Kate Olsson with the support of Judit Takács. The scoping review was performed by researchers from the Vaccine Confidence Project, at the London School of Hygiene & Tropical Medicine (contract number ECD8894). Authors: Emilie Karafillakis, Clarissa Simas, Sam Martin, Sara Dada, Heidi Larson. Acknowledgements ECDC would like to acknowledge contributions to the project from the expert reviewers: Dan Arthus, University College London; Maged N Kamel Boulos, University of the Highlands and Islands, Sandra Alexiu, GP Association Bucharest and Franklin Apfel and Sabrina Cecconi, World Health Communication Associates. ECDC would also like to acknowledge ECDC colleagues who reviewed and contributed to the document: John Kinsman, Andrea Würz and Marybelle Stryk. Suggested citation: European Centre for Disease Prevention and Control. Systematic scoping review on social media monitoring methods and interventions relating to vaccine hesitancy. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-452-4 doi: 10.2900/260624 Catalogue number TQ-04-20-076-EN-N © European Centre for Disease Prevention and Control, 2020 Reproduction is authorised, provided the -
(12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms. -
ADHD: Substance Abuse
1/13/2012 Overview of Mental Health Medications for Children and Adolescents Module 6 Medications and Drugs of Abuse 1 1967 Now Alcohol Alcohol Marijuana Marijuana Cocaine Cocaine Methamphetamine Crank LSD LSD Rohypnol/GHB Quaaludes Inhalants Glue Ecstasy Designer drugs Prescription drugs 2 ADHD: Substance Abuse Children with untreated ADHD are twice as likely to develop substance abuse by age 18-20 than those who were treated Treatment with stimulants in adolescents with ADHD and comorbid substance abuse improves the ADHD and does not worsen the substance abuse disorder 3 1 1/13/2012 Drug Lingo Resources www.noslang.com www.teenchatterdecoder.com 4 2001 2003 2004 2008 Cocaine 967.6 kg 379.6 1308.1 1016.1 kg kg kg Heroin 15.8 kg 60 kg 39.3 kg 3.3 kg Meth 77.4 kg 88 kg 83.9 kg 65 kg Meth Labs 51 226 261 78 Ecstasy Tablets 52951 8393 5 Cocaine Bulk cocaine transported into state – crack made locally Primary sources – Texas and California Heroin Sources of supply – Chicago, New York and Southwest Purity in GA ranges between 52-65% Greater Hispanic involvement www.dea.gov 6 2 1/13/2012 Drug Use in Georgia Methamphetamine Atlanta, Dalton, Gainesville showing increases as well as southwest and eastern counties Increased availability of ICE in Atlanta area Club drugs MDMA, GHB and ketamine readily available (gyms, college campuses and associated ‘hang outs’ LSD usually around school settings – imported from West Coast by US postal service or express mail Emerging trend – ‘candy tripping’ – combining LSD and MDMA -
Download Product Insert (PDF)
PRODUCT INFORMATION Deracoxib Item No. 27371 CAS Registry No.: 169590-41-4 O H2N Formal Name: 4-[3-(difluoromethyl)-5-(3-fluoro- S O 4-methoxyphenyl)-1H-pyrazol-1- yl]-benzenesulfonamide F Synonym: SC-59046 O MF: C17H14F3N3O3S 397.4 FW: N Purity: ≥98% N UV/Vis.: λmax: 256 nm Supplied as: A solid Storage: -20°C F Stability: ≥2 years F Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Deracoxib is supplied as a solid. A stock solution may be made by dissolving the deracoxib in the solvent of choice, which should be purged with an inert gas. Deracoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of deracoxib in ethanol is approximately 3 mg/ml and approximately 10 mg/ml in DMSO and DMF. Deracoxib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, deracoxib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Deracoxib has a solubility of approximately 0.1 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) and selective inhibitor of COX-2 1 (IC50s = 0.63 and 23 μM for COX-2 and COX-1, respectively). In vivo, deracoxib (0.3-10 mg/kg) increases weight bearing and decreases lameness and joint effusion in a canine model of urate crystal-induced intraarticular synovitis.2 Deracoxib induces less lesion formation in the gastric mucosa of healthy canines than aspirin (Item No. -
Anesthesia and Analgesia in Laboratory Animals
GUIDELINES ON ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS University of South Florida provides the following guidelines for use by IACUC-certified faculty and staff. CONTENTS PAGE A. Background……………………………………………………….…………………………… 1 B. Definitions....……………………………………………………..…………………………….. 2 C. General Considerations……………………………………….,…………………………….. 3 D. Controlled Substances……………………………………….……………………………… 3 E. Pre-Anesthetic Treatments………………………………….………………………………. 4 F. General Anesthetics………………………………………….………………………………. 4 G. Neuromuscular Blocking Agents………………………….……………………………….. 5 H. Monitoring Anesthesia…………………………………….…………………………………. 6 I. Analgesics……………………………………………………………………………………… 7 J. Comments regarding Anesthetics and Analgesics……………………………………... 7 REFERENCE TABLES PAGE I. Signs of Pain and Distress in Laboratory Animals………………………………………… 10 II. Commonly Used Anesthetics and Analgesics for Mice….………..…...….………...…… 11 III. Commonly Used Anesthetics and Analgesics for Rats……………………………...…… 12 IV. Commonly Used Anesthetics and Analgesics for Gerbils……….……………..…….. 13 V. Commonly Used Anesthetics and Analgesics for Hamsters…….……………..……. 14 VI. Commonly Used Anesthetics and Analgesics for Guinea Pigs….…………….….……. 15 VII. Commonly Used Anesthetics and Analgesics for Rabbits.……...…………….………… 16 VIII. Commonly Used Anesthetics and Analgesics for Dogs.…………………….…………… 17 IX. Commonly Used Anesthetics and Analgesics for Cats.……………………..…………… 18 X. Commonly Used Anesthetics and Analgesics for Pigs ..……………..….………………..19 XI. Commonly Used Anesthetics and Analgesics